.jpeg)
The anti-cancer effect of Entrectinib
Entrectinib (Entrectinib) is a tyrosine kinase inhibitor that acts on several receptors. It acts as an ATP competitor and inhibits the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, as well as the proto-oncogene tyrosine protein kinase ROS1 and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation through downstream signaling of mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and phospholipase C-γ. ALK produces similar signaling by adding downstream JAK/STAT activation. Inhibition of these pathways inhibits cancer cell proliferation and tilts the balance toward apoptosis, resulting in tumor size reduction.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
